Gilead Sciences to pay $300 million for nearly half of Tizona, has option to buy the rest for $1.25 billion – MarketWatch

Gilead Sciences Inc
.
GILD, -1.05%.
announced Tuesday an offer to purchase a 49.9% stake in independently held cancer treatment designer Tizona Therapeutics Inc. for $300 million. Gilead also got an o. [+902 chars]